SORD/Sorbitol Dehydrogenase Drug Discovery Landscape & Assay Solutions

  • By admin
  • 23 Sep 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathy and Metabolic Disease Development.

TarMart Solution Ecosystem & Related Targets

"Comprehensive reagent toolkit for SORD drug discovery. Select your modality below:"

Component / Network Product Description Product Link
Antigen SORD Recombinant Protein (WT)
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed.		 View SORD Products
Gene Delivery SORD Promise-ORF / Lentivirus
Full-length ORF for stable cell line generation and rescue assays.		 View SORD Products
Benchmark Ab Anti-SORD Recombinant Antibody
Recombinant positive control for western blot, ELISA, and IHC.		 View SORD Products
Validator SORD siRNA Set
For knockdown verification in target specificity assays.		 View SORD Products
Related Target A AKR1B1 (Aldose Reductase)
Upstream enzyme in the polyol pathway; primary target for Substrate Reduction Therapy (SRT) in SORD deficiency.		 View AKR1B1 Products
Related Target B HK1 (Hexokinase 1)
Sorbitol pathway bypass enzyme; critical for metabolic flux analysis in neuropathic models.		 View HK1 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Enzymatic Activity Quantification High-purity active recombinant SORD WT protein with verified sequence and high solubility.
Disease Model Rescue Verification Lentivirus-based full-length SORD expression particles to validate intracellular sorbitol reduction.
Lack of Controls Recombinant benchmark antibodies and validated siRNA sequences included for robust assay baselines.
False Positives Sequence-verified mutant SORD controls to verify assay specificity and rule out off-target enzymatic activity.

Live SORD R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for SORD-related therapeutics is intensifying, with major players shifting focus from traditional metabolic indications to hereditary neuropathies, specifically SORD deficiency (Charcot-Marie-Tooth disease type 2D, CMT2D). SORD is an intracellular enzyme that converts sorbitol to fructose. Loss-of-function mutations in SORD lead to toxic accumulation of sorbitol in peripheral nerves. As first-generation therapies reach the clinic, the next wave of R&D is targeting both substrate reduction therapy (SRT) via Aldose Reductase (AKR1B1) inhibitors and direct SORD gene replacement therapies.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule (ARI) Applied Therapeutics, Registone SORD Neuropathy (CMT2D), Diabetic Neuropathy Enzymatic screening assays (Need high-purity AKR1B1 and SORD proteins)
Gene Therapy (AAV/Lenti) Exicure, Academic Institutions SORD Deficiency (CMT2D) In vitro rescue assays (Need SORD Lentivirus for stable expression)
RNA Therapeutics (siRNA) Alnylam, Ionis Metabolic Disorders, Fructose-driven NAFLD Knockdown validation (Need SORD siRNA and benchmark antibodies)